Skip to main content

New Products

  • Rolaids to once again spell relief for heartburn remedy sets

    PARIS — Sanofi US and its consumer health business Chattem on Monday unveiled plans to re-introduce the iconic Rolaids heartburn-relief brand to the U.S. market. The brand returns after a three-year hiatus in the marketplace and follows Chattem's acquisition of Rolaids earlier this year.  

  • Actavis launches generic post-shingles pain patch

    PARSIPPANY, N.J. — Actavis has launched a generic drug for post-shingles pain under an agreement with the branded drug's manufacturers, the company said Monday.

    Actavis announced the launch of generic lidocaine topical patches in the 5% strength under a settlement agreement with Endo Pharmaceuticals and Teikoku Seiyaku Co. The drug is a generic version of Lidoderm, and Actavis said it was likely the first company to win approval for the generic from the Food and Drug Administration, thus entitling it to 180 days in which to compete exclusively against the branded version.

  • FDA approves Sun ulcer drug

    MUMBAI, India — The Food and Drug Administration has approved a drug made by Sun Pharmaceutical Industries for ulcers, Sun said.

    Sun announced the approval of lansoprazole delayed-release capsules in the 15-mg and 30-mg strengths.

    The drug is a generic version of Takeda's Prevacid delayed-release capsules, which are used for treatment lasting up to four weeks for healing and symptom relief of active duodenal ulcers.

    Various versions of the drug have annual sales of about $430 million per year, according to Sun.

     

  • Orexo U.S. launches Zubsolv for opioid dependence

    NEW YORK — A drug for treating opioid dependence has been launched, the manufacturer said Monday.

    Orexo announced the introduction of Zubsolv (buprenorphine; naloxone) sublingual tablets for the maintenance treatment of opioid dependence. The drug is designed for use as part of a broader treatment regimen that combines drug therapy and counseling.

  • FDA approves first generic version of Genentech chemotherapy pill

    SILVER SPRING, Md. — The Food and Drug Administration has approved a generic chemotherapy pill for treating colorectal and breast cancers, the agency said Monday.

    The FDA announced the approval of Teva Pharmaceutical Industries' capecitabine tablets in the 150-mg and 500-mg strengths. The drug is used to treat cancers that have metastasized, meaning they've spread to other parts of the body.

    The drug is a generic version of Xeloda, made by Roche division Genentech. According to IMS Health, Xeloda had sales of $706.2 million last year.

     

  • ChapStick introduces new Hydration Lock for healthier, nourished lips

    Madison, N.J. — ChapStick, part of the Pfizer portfolio of consumer brands, on Friday announced a new lip balm with advanced moisturizing and anti-aging ingredients.

  • Actavis launches generic version of Opana ER

    PARSIPPANY, N.J. — Actavis has launched a generic version of an extended-release opioid painkiller, the company said.

    The drug maker announced the launch of oxymorphone extended-release tablets in the 5-mg, 10-mg, 20-mg, 30-mg and 40-mg strengths. Actavis received approval for the drug in July.

    The drug is a generic version of Endo's Opana ER. Endo is currently suing Actavis, alleging that Actavis' generic infringes some of its patents. The drug is used for around-the-clock pain relief.

  • Clif launches a new line of on-the-go single-serve performance drinks

    EMERYVILLE, Calif. — Clif on Thursday launched a new line of performance drinks: Clif Shot Electrolyte Hydration Drink Mix and Clif Shot Protein Recovery Drink Mix. In combination with Clif Shot Bloks and Clif Shot Energy Gel, the Clif Shot Portfolio now effectively covers athletes’ needs before, during and after activity.

X
This ad will auto-close in 10 seconds